3 Stocks Moving The Health Care Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the sector include Amgen ( AMGN), up 1.1%, AstraZeneca ( AZN), up 1.0%, Gilead ( GILD), up 0.9%, Medtronic ( MDT), up 0.9% and Eli Lilly and ( LLY), up 0.8%. On the negative front, top decliners within the sector include Alere ( ALR), down 13.5%, Catamaran ( CTRX), down 3.1%, Taro Pharmaceutical Industries ( TARO), down 2.7%, ResMed ( RMD), down 1.9% and Teva Pharmaceutical Industries ( TEVA), down 1.7%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. NPS Pharmaceuticals ( NPSP) is one of the companies pushing the Health Care sector higher today. As of noon trading, NPS Pharmaceuticals is up $1.54 (5.5%) to $29.40 on average volume. Thus far, 943,386 shares of NPS Pharmaceuticals exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $27.66-$29.59 after having opened the day at $28.18 as compared to the previous trading day's close of $27.86.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS Pharmaceuticals has a market cap of $3.0 billion and is part of the drugs industry. Shares are down 8.2% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates NPS Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full NPS Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biomarin Pharmaceutical ( BMRN) is up $1.24 (2.0%) to $63.19 on average volume. Thus far, 472,742 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $61.64-$63.30 after having opened the day at $61.96 as compared to the previous trading day's close of $61.95.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $9.0 billion and is part of the drugs industry. Shares are down 12.1% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Humana ( HUM) is up $1.30 (1.1%) to $120.10 on average volume. Thus far, 620,499 shares of Humana exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $118.26-$120.18 after having opened the day at $118.70 as compared to the previous trading day's close of $118.80.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $18.1 billion and is part of the health services industry. Shares are up 15.1% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid

Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid

'Mad Money' Lightning Round: Ambarella Is Like Putting a Gun to Your Head

'Mad Money' Lightning Round: Ambarella Is Like Putting a Gun to Your Head

Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead

Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead